EU PROJECTS

The main objective of the project is to develop and strengthen research and innovation capabilities and use advanced technologies to develop the company’s competitive potential by conducting R&D work on innovative material with radioprotective properties until December 2026. The research goal of the project will be to develop the formula of the raw material for cosmetic and pharmaceutical applications based on TEMPOL (a chemical compound with radioprotective properties). The final product will be aimed at neutralising the toxicity of radiation by protecting the epidermis from high-energy radiation. Thanks to the innovative formula, the product has a chance to become a breakthrough discovery both in Poland and in the world. Thanks to the use of lipid molecules as carriers of the active substance in the study, we increase the effectiveness of the preparation, and thus the innovativeness of the research conducted as part of the Consortium. The lipid base created as part of the project will have a wide range of preventive and therapeutic applications in response to the negative effects of radiation – including radiological radiation. The purpose and scope of the project are therefore consistent with the Regional Intelligent Specialisation of Silesia,  in the field of medicine. The project is implemented by a consortium, whose leader is a small company operating in the medical and biotechnology industry, and the partner is a leading research unit implementing projects at the intersection of research and implementation.

The aim of the project is to develop a globally innovative, new drug, liposomal iron for oral administration with a high degree of absorption. The process of producing such liposomes will be based on the patented LipoShell technology. This goal will be achieved through research and development and, at a later stage, implementation of an oral liposomal iron preparation, intended for use in the treatment of iron deficiency in patients diagnosed with anaemia associated with kidney disease, cancer and postpartum anaemia. As a result of R&D work, a new and unique liposomal form of iron will be created, analytical methods, a manufacturing process and prototypes of components necessary for the pilot production line of the nanostructures with iron will be developed. The necessary chronology of tasks has been preserved, i.e. performing industrial research on liposomal iron formulations, during which knowledge and documentation will be created for the creation of module 3 CTD. Then the stability of the preparations, quality in in vitro and safety in in vivo studies will be examined. The GMP infrastructure owned by the Applicant Lipid Systems will be used to launch the pilot production of the drug and then clinical trials will be conducted. The product will eventually be registered as a drug. The implementation of the project will lead to the implementation of the following innovations: 1) product, through the development and implementation of a new product using patented LipoShell technology, 2) process, through the development and implementation of a new manufacturing process. The liposomal form of iron resulting from the project will be characterised by high bioavailability and effectiveness and reduced side effects.